AOC 1001 is based on Avidity’s Antibody Oligonucleotide Conjugates (AOCs™) platform, designed to treat diseases of high unmet need by combining the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide therapies . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge